HOME >> BIOLOGY >> NEWS
Enzymes Targeted As Key To Understanding Drug Interactions

You go to one doctor for your back problem. You see another for high blood pressure. Perhaps you consult a third for a nagging sinus infection. As part of your treatment, each writes a prescription or two. The result can be an array of pill bottles on your bathroom counter or breakfast table, perhaps augmenting your usual arsenal of over-the-counter supplements and pain and cold remedies.

How is the patient -- or the health care professional -- to know when the potential exists for a serious, even life-threatening, interaction between medications? Or when one drug may render another ineffective? News stories have highlighted the problem of pharmacists who failed to question prescriptions for dangerous drug combinations, and pharmacists complain of computer programs that fail to give them adequate warning of possible interactions.

A notorious example of a potentially deadly drug duo was Seldane, a popular antihistamine, and erithromycin, a common antibiotic, which when taken together could produce sometimes fatal heart problems. The U.S. Food and Drug Administration (FDA) has recommended that Seldane be withdrawn from the market.

Prevention of drug interactions, say researchers at the University of Washington School of Pharmacy, lies in learning how the human body processes each drug.

The school has recently established a formal Program in Drug Interactions, tapping the expertise of 22 faculty members believed to be the largest group of experts in the world on drug interactions.

The UW investigators are seeking systematic knowledge of how various enzymes -- biochemical catalysts produced by the body -- metabolize drugs. Their research is producing an understanding of the potential for adverse effects among thousands of drug combinations.

"Pharmacists have had to remember hundreds of pairs of drugs that interact," said the program's director, Dr. Rene Levy, professor and chair of pharmaceutics. "But there was a shift in our knowedge
'"/>

Contact: Laurie McHale
lmchale@u.washington.edu
206-543-3620
University of Washington
28-May-1997


Page: 1 2

Related biology news :

1. Constructing "Designer" Plant Enzymes
2. Engineering New Enzymes
3. Spinach Enzymes Neutralize Explosives
4. Worm Wizardry: Worlds Most Heat-Tolerant Creature Suggests Enzymes For Drugs OrIndustry, UD Prof Says
5. Targeted therapy knocks out pediatric brain cancer in mice
6. Targeted therapy for lung cancer patients shows promise in extending lives
7. Targeted immunotherapy eradicates cancer in mice
8. Targeted radiation to liver tumors spares tissue, improves quality of life
9. Targeted Genetics presents data on arthritis gene therapy
10. Targeted genetics presents promising data from cystic fibrosis clinical trial
11. Targeted Genetics presents clinical data on E1A cancer gene therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
Breaking Biology Technology:
Cached News: